Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate) in P-III QUARTZ Study for Inadequately Controlled Asthma

Shots:

• The P-III QUARTZ study results involves assessing of QMF149 (150/80 Mu g) vs mometasone furoate (200 Mu g) delivered via Breezhaler & Twisthaler in 802 adult and adolescent patients in a ratio (1:1) with inadequately controlled asthma respectively
• The P-III QUARTZ study results: @12wks. met its 1EPs & 2EPs; improvement in lung function; improvements in evening PEF (26.1 L/min); improvements in asthma control as measured by ACQ-7 (74.7% vs 64.9%); AEs (32.3% vs 38.3%)
• QMF149 (qd) is an inhaled fixed-dose combination therapy delivered with the dose-confirming Breezhaler device and is evaluated under Novartis’ P-III PLATINUM Program. Novartis enters into an exclusive license agreement with Merck for mometasone furoate to use in QMF149 candidate

Click here to read full press release/ article | Ref: Novartis | Image: Pinterest